Details of the Drug

General Information of Drug (ID: DM2RX0I)

Drug Name

Abametapir

Synonyms

5,5'-Dimethyl-2,2'-bipyridine; 1762-34-1; 5,5'-Dimethyl-2,2'-dipyridyl; 5,5'-Dimethyl-2,2'-bipyridyl; 6,6'-Bi-3-picoline; 2,2'-BIPYRIDINE, 5,5'-DIMETHYL-; HA-44; 6,6'-Di-3-picolyl; 6,6'-Di-3-picoline; UNII-6UO390AMFB; 5-methyl-2-(5-methylpyridin-2-yl)pyridine; MFCD01740554; 6UO390AMFB; CHEMBL2205807; 5,5'-dimethyl-2,2'-bipyridinyl; 5,5 -Dimethyl-2,2 -bipyridine; Xeglyze; BRN 0123183; Abametapir [USAN:INN]; Xeglyze(Abametapir); Xeglyze (TN); PubChem24353; Abametapir (USAN/INN); ACMC-209eb4; SCHEMBL351152; HA44; 2,2 -Bis-(5-methylpyridyl); DTXSID00170095; ZINC403335; 9238AA; ANW-22814; BDBM50401351; LT0042; s5752; 5,5''-Dimethyl-2,2''-bipyridine; AKOS005257775; CS-W004546; DB11932; MCULE-8581798506; SB17220; 5,5 inverted exclamation marka-Dimethyl-2,2 inverted exclamation marka-dipyridyl; 5,5'-Dimethyl-2,2'-dipyridyl, 98%; AK-63331; DS-15219; SY052805; FT-0689891; D10687; W-108621; Q27265547; 5,5 inverted exclamation mark -Dimethyl-2,2 inverted exclamation mark -bipyridyl

Indication

Disease Entry	ICD 11	Status	REF
Head and body lice	1G00.0	Approved	[1]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

184.24

Topological Polar Surface Area (xlogp)

2.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 121 mcgh/L [2]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 41 mcg/L [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 71 +/- 40 hours [2]
Metabolism: The drug is metabolized via the CYP1A2 [2]

Chemical Identifiers

Formula: C12H12N2
IUPAC Name: 5-methyl-2-(5-methylpyridin-2-yl)pyridine
Canonical SMILES: CC1=CN=C(C=C1)C2=NC=C(C=C2)C
InChI: InChI=1S/C12H12N2/c1-9-3-5-11(13-7-9)12-6-4-10(2)8-14-12/h3-8H,1-2H3
InChIKey: PTRATZCAGVBFIQ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 15664
CAS Number: 1762-34-1
DrugBank ID: DB11932
TTD ID: D5IS6V
ACDINA ID: D00802

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Matrix metalloproteinase (MMP)	TT1GHVO	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Abametapir (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Gilteritinib	DMWQ4MZ	Moderate	Decreased metabolism of Abametapir caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[13]
Oliceridine	DM6MDCF	Moderate	Decreased metabolism of Abametapir caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[13]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Abametapir caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Pexidartinib	DMS2J0Z	Moderate	Decreased metabolism of Abametapir caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[13]
Alpelisib	DMEXMYK	Moderate	Decreased metabolism of Abametapir caused by Alpelisib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
PF-04449913	DMSB068	Moderate	Decreased metabolism of Abametapir caused by PF-04449913 mediated inhibition of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[13]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of Abametapir caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[13]
Tazemetostat	DMWP1BH	Moderate	Decreased metabolism of Abametapir caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[13]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Abametapir caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[13]
Avapritinib	DMK2GZX	Moderate	Decreased metabolism of Abametapir caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[13]
MK-1439	DM215WE	Moderate	Decreased metabolism of Abametapir caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
TP-434	DM5A31S	Moderate	Decreased metabolism of Abametapir caused by TP-434 mediated inhibition of CYP450 enzyme.	Infectious gastroenteritis/colitis [1A40]	[13]
Pemigatinib	DM819JF	Moderate	Decreased metabolism of Abametapir caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[13]
Brigatinib	DM7W94S	Moderate	Decreased metabolism of Abametapir caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[13]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Abametapir caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[14]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Abametapir caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[13]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of Abametapir caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[13]
Rimegepant	DMHOAUG	Moderate	Decreased metabolism of Abametapir caused by Rimegepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[13]
Siponimod	DM2R86O	Moderate	Decreased metabolism of Abametapir caused by Siponimod mediated inhibition of CYP450 enzyme.	Multiple sclerosis [8A40]	[13]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Abametapir caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[13]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Abametapir caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[13]
Upadacitinib	DM32B5U	Moderate	Decreased metabolism of Abametapir caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[13]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Abametapir caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[13]
Fluticasone	DMGCSVF	Moderate	Decreased metabolism of Abametapir caused by Fluticasone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[13]
-----------


⏷ Show the Full List of 24 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Benzyl alcohol	E00010	244	Antimicrobial preservative; Solvent
Butylated hydroxytoluene	E00336	31404	Antioxidant
Trolamine	E00151	7618	Alkalizing agent; Emulsifying agent
Polysorbate 20	E00664	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Water	E00035	962	Solvent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Abametapir 0.74% lotion	0.74%	Lotion	Topical

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2	FDA Approved Drug Products: Xeglyze (Abametapir) topical lotion
3	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4	Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93.
5	Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Mass Spectrom. 2004 Mar;39(3):277-88.
6	Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 1999 Mar15;59(6):1231-5.
7	CIINE Reflects Collagenase-Specific CII Breakdown in Cartilage Explant and Whole Body of Canine. Biomark Insights. 2013; 8: 77-83.
8	Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg. 2004 Feb;39(2):432-9.
9	ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res. 2000 Apr;49(4):144-6.
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11	WO patent application no. 2006,1139,93, Matrix metalloproteinase inhibitors of tgfss -induced subcapsular cataract formation.
12	US patent application no. US20080187572 A1.
13	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
14	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.